High-Risk MDS and Secondary AML with Hetty Carraway, MD, MBA and Amer Zeidan, MD @AAMDSIF
High-Risk MDS and Secondary AML with Hetty Carraway, MD, MBA and Amer Zeidan, MD @AAMDSIF
Uploaded June 2026 | Updated September 2026, 3 days ago
From the 2026 International Bone Marrow Failure Disease Scientific Symposium
Dr. Hetty Carraway and Dr. Amer Zeidan discuss the research presented in their session about treatment options for high-risk MDS, lessons learned from recent clinical trials, and promising directions for improving therapies.

For patients: Use the toolkit linked below to help you manage your treatment.
MDS Toolkit: aamds.org/mds/toolkit
High-Risk MDS and Secondary AML with Hetty Carraway, MD, MBA and Amer Zeidan, MDWhat is the IPSS-M for MDS? With Dr. Gail RobozMucocutaneous GVHDMDS and Non-Transplant Therapies from the Patient and Family Conference in Salt Lake City, UT, 2023Cytopenia Management of Low Risk MDS, or Myelodysplastic SyndromesAthletic Service Member Conquers Aplastic Anemia and MDS with TransplantAAMDSIF 40th Anniversary Summit: The Future of Clinical Trials Panel DiscussionTreatment Decisions in Chronic GVHDCLONALITY IN ACQUIRED BONE MARROW FAILURE, PNH, VEXASAAMDSIF 40th Anniversary Summit: Advances in the Science and Treatment of Aplastic AnemiaGrant Impact Story: Dr. Matthew WalterLiving with PNH from the 2022 Buffalo Patient and Family Conference, presented by Bart Scott, MD
AAMDSIF |

High-Risk MDS and Secondary AML with Hetty Carraway, MD, MBA and Amer Zeidan, MD

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER